IL134056A0 - Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections - Google Patents

Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections

Info

Publication number
IL134056A0
IL134056A0 IL13405698A IL13405698A IL134056A0 IL 134056 A0 IL134056 A0 IL 134056A0 IL 13405698 A IL13405698 A IL 13405698A IL 13405698 A IL13405698 A IL 13405698A IL 134056 A0 IL134056 A0 IL 134056A0
Authority
IL
Israel
Prior art keywords
antibiotic
treatment
combination
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL13405698A
Other languages
English (en)
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Publication of IL134056A0 publication Critical patent/IL134056A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13405698A 1997-07-23 1998-07-21 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections IL134056A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5347097P 1997-07-23 1997-07-23
PCT/US1998/015257 WO1999004809A1 (fr) 1997-07-23 1998-07-21 Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques

Publications (1)

Publication Number Publication Date
IL134056A0 true IL134056A0 (en) 2001-04-30

Family

ID=21984478

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13405698A IL134056A0 (en) 1997-07-23 1998-07-21 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections

Country Status (20)

Country Link
US (1) US20020006406A1 (fr)
EP (1) EP1001804B1 (fr)
JP (1) JP2001510805A (fr)
KR (1) KR20010022237A (fr)
CN (1) CN1269727A (fr)
AT (1) ATE316794T1 (fr)
AU (1) AU754806B2 (fr)
BR (1) BR9811535A (fr)
CA (1) CA2297083C (fr)
DE (1) DE69833377T2 (fr)
HU (1) HUP0002662A3 (fr)
IL (1) IL134056A0 (fr)
NO (1) NO320884B1 (fr)
NZ (1) NZ502359A (fr)
PL (1) PL338178A1 (fr)
RU (1) RU2234940C2 (fr)
SK (1) SK732000A3 (fr)
TW (1) TWI235656B (fr)
WO (1) WO1999004809A1 (fr)
ZA (1) ZA986593B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
AU2001259205A1 (en) * 2000-04-28 2001-11-12 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
JP2006507850A (ja) * 2002-03-26 2006-03-09 バイオシネクサス インコーポレイテッド 細菌バイオフィルムの酵素破壊
EP1567868A4 (fr) * 2002-12-02 2008-02-06 Biosynexus Inc Acide teichoique a paroi en tant que cible pour therapies et vaccins anti-staphylococciques
AP2005003346A0 (en) * 2002-12-10 2005-06-30 Biosynexus Inc Topical anti-infective formulations
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
EP1850867A1 (fr) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Methode de traitement d'une infection par staphylocoque dore
WO2006110776A2 (fr) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Compositions a base de polymere et conjugues d'agents antimicrobiens
WO2007113499A1 (fr) * 2006-03-31 2007-10-11 The University Court Of The University Of St Andrews Compositions antimicrobiennes comprenant un peptide cationique et une endopeptidase de glycylglycine
DK2037946T3 (en) 2006-05-05 2015-04-27 Gangagen Inc ANTIMICROBIAL ACTIVITIES DERIVED BY PHAGER
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009150171A1 (fr) * 2008-06-10 2009-12-17 Profos Ag Procédé de traitement de maladies inflammatoires
US11155801B2 (en) 2013-08-06 2021-10-26 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
RU2572341C2 (ru) * 2013-09-20 2016-01-10 Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) АНТИБИОТИК ИНА 5812, ШТАММ-ПРОДУЦЕНТ Streptomyces roseoflavus ИНА-Ас-5812 И СПОСОБ ПОЛУЧЕНИЯ АНТИБИОТИКА
EP3485899A4 (fr) * 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze Composition thermostable possédant une action antivirale et antibactérienne, et utilisation de celle-ci
US11565024B2 (en) 2017-11-16 2023-01-31 Georgia Tech Research Corporation Lysostaphin containing synthetic hydrogel carriers for bone repair
CN110917339B (zh) * 2019-12-27 2023-07-07 遵义医学院附属医院 一种溶葡萄球菌酶凝胶剂及其在mrsa感染创面中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
AU623864B2 (en) * 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections

Also Published As

Publication number Publication date
KR20010022237A (ko) 2001-03-15
ZA986593B (en) 1999-02-04
WO1999004809A1 (fr) 1999-02-04
DE69833377T2 (de) 2006-11-16
RU2234940C2 (ru) 2004-08-27
EP1001804A1 (fr) 2000-05-24
US20020006406A1 (en) 2002-01-17
AU754806B2 (en) 2002-11-28
NO20000314L (no) 2000-03-16
CA2297083C (fr) 2007-10-30
CN1269727A (zh) 2000-10-11
SK732000A3 (en) 2001-03-12
PL338178A1 (en) 2000-10-09
EP1001804B1 (fr) 2006-02-01
NO20000314D0 (no) 2000-01-21
TWI235656B (en) 2005-07-11
HU0002662D0 (en) 2000-08-28
ATE316794T1 (de) 2006-02-15
CA2297083A1 (fr) 1999-02-04
DE69833377D1 (de) 2006-04-13
HUP0002662A2 (hu) 2000-12-28
NZ502359A (en) 2005-02-25
HUP0002662A3 (en) 2003-08-28
BR9811535A (pt) 2000-08-29
NO320884B1 (no) 2006-02-06
JP2001510805A (ja) 2001-08-07
AU8509598A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
HU0002662D0 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
WO2002051424A8 (fr) Medicaments contre les defaillances articulaires
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
MX9701683A (es) Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.
FI963232A0 (fi) Antimikrobisena aineena käytettävä hapotettu nitriitti
AU2119200A (en) Medicament
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
MX9803692A (es) Derivados de eritromicina triciclicos.
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
AP2002002652A0 (en) The use of azalide antibiotic composition for treating or preventing a bacterial or protozoal infection in mammals.
WO2000000214A3 (fr) Preparations pharmaceutiques destinees a combattre ou a prevenir les infections superficielles provoquees par des micro-organismes
WO2001010387A3 (fr) Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
MX9708611A (es) Compuestos de dialquiltiacumicina.
WO2000030435A3 (fr) Traitement contre la loque
AU6633596A (en) Improved therapeutic agents
EP1114826A3 (fr) Macrolides antibactériennes et prokinétiques
BG103958A (en) Pharmaceutical compositions of thioxanide and nitazoxanide
EP1671644A3 (fr) Compositions pharmaceutiques contenant uniquement ou en combinaison avec un antibiotique de la lysostaphin pour le traitement des infections à staphylocoques
AUPP325398A0 (en) Improved method for eradicating h. pylori
WO2002000839A3 (fr) Novispirines: peptides antimicrobiens
GEP20033144B (en) Hygromycin A Derivatives as Antibacterial Agents
AU5284999A (en) New injectable formulations containing ramoplanin
WO2004000864A3 (fr) Cetolides a substitution 11-c